An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Trial Profile

An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Palbociclib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jun 2017 Safety results of the Canadian Expanded Access Program (n=96), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 10 Jun 2016 Status changed from recruiting to completed.
    • 07 Jun 2016 Results assessing palbociclib's effect on estrogen receptor mutations (n = 17) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top